Search Results - diagnostic+markers+%3e+cancer

14 Results

Sort By:

Summary: A UCLA researcher in the Department of Medicine, Hematology Oncology has developed a computational framework to model subcellular orientation for spatial biology Background: Spatial biology allows researchers to map the coordinates of proteins with subcellular resolution, revolutionizing our understanding of disease. Critical cellular processes...

Published: 6/3/2026 | Updated: 6/3/2026 | Inventor(s): Katie Campbell, Daniel Chen, Taejus Yee

Keywords(s):

Category(s): Diagnostic Markers, Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Platforms, Platforms > Diagnostic Platform Technologies, Software & Algorithms, Software & Algorithms > Image Processing, Software & Algorithms > Programs, Software & Algorithms > Bioinformatics, Software & Algorithms > Data Analytics, Software & Algorithms > Digital Health

UCHL1 Inhibitors, Modifications, and Uses Thereof (UCLA Case No. 2026-123)

UCLA researchers in the Department of Molecular & Medical Pharmacology and have developed novel, highly potent small-molecule inhibitors of UCHL1 that selectively suppress tumor growth and metastasis in aggressive cancers with favorable in vivo safety profiles. BACKGROUND: Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is a dual-function enzyme...

Published: 3/11/2026 | Updated: 3/11/2026 | Inventor(s): Tanya Stoyanova, Michael Jung

Keywords(s):

Category(s): Diagnostic Markers > Cancer, Therapeutics > Oncology, Therapeutics > CNS and Neurology, Therapeutics > Oncology > Oncology (Small Molecules)

Engineered Gamma Delta T-Cells and Methods of Making and Using Thereof (UCLA Case No. 2020-913)

UCLA researchers in the Department of Molecular Immunology & Molecular Genetics have developed gamma delta (gd) T cell receptor gene-modified immune cells derived from stem and progenitor cells that enable scalable, off-the-shelf allogeneic cell therapies with broad therapeutic potential. BACKGROUND: Cell-based immunotherapies have demonstrated...

Published: 3/4/2026 | Updated: 3/4/2026 | Inventor(s): Lili Yang, Derek Lee, Tyler Halladay

Keywords(s):

Category(s): Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Life Science Research Tools > Cell Lines, Therapeutics > Oncology, Therapeutics > CNS and Neurology, Therapeutics > Hematology, Therapeutics > Autoimmune, Therapeutics > Gene Therapy And Editing, Therapeutics > Stem Cells And Regenerative Medicine, Therapeutics > Infectious Diseases

Microbial Regulation of Immune Tolerance and Risk for Cancer (UCLA Case No. 2026-153)

UCLA researchers in the Department of Integrative Biology and Physiology have identified a microbiome-driven signaling pathway that increases serotonin production and colorectal cancer (CRC) risk which may serve as a valuable therapeutic target for CRC. BACKGROUND: The gut microbiome plays a central role in regulating host physiology through interactions...

Published: 5/22/2026 | Updated: 3/4/2026 | Inventor(s): Elaine Hsiao, Lewis Yu

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Gastroenterology, Therapeutics > Immunology And Immunotherapy, Diagnostic Markers > Cancer

Compositions and Methods to Modulate MAVS-Mediated Immunity (UCLA Case No. 2026-096)

UCLA researchers in the Department of Microbiology, Immunology, and Molecular Genetics have developed methods to target TOM70, a mitochondrial outer membrane protein, to selectively modulate innate immune signaling and control pathological or protective immune responses across a range of clinical conditions. BACKGROUND: Innate immune detection of viral...

Published: 2/18/2026 | Updated: 2/18/2026 | Inventor(s): Lena Pernas

Keywords(s):

Category(s): Diagnostic Markers > Targets And Assays, Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Platforms > Diagnostic Platform Technologies, Therapeutics > Oncology, Therapeutics > Infectious Diseases, Therapeutics > Immunology And Immunotherapy, Therapeutics > Inflammation And Inflammatory Diseases, Therapeutics > Autoimmune, Therapeutics > Vaccines

An Acoustic Device for Large Area Single Cell Trapping and Selective Release (Case No. 2025-047)

Summary: UCLA researchers in the Department of Mechanical and Aerospace Engineering have developed an acoustic microfluidic platform that offers a cost-effective and practical approach for handling individual cells at the microscale. Background: Single-cell manipulation is essential for understanding cellular behavior, disease progression, and therapeutic...

Published: 1/13/2026 | Updated: 1/13/2026 | Inventor(s): Pei-Yu Chiou, Xiang Zhang

Keywords(s): acoustic microfluidics, acoustic potential wells, acoustics, cell proliferation, cell viability, Diagnostic Platform Technologies (E.G. Microfluidics), diagnostic platforms, Digital Microfluidics, disposable microfluidic platforms, high throughput, high throughput assays, high throughput testing, High-Content Screening, high-throughput cell handling, low-cost fabrication, MEMS, MEMS metasurface, micro-electromechanical systems (MEMS), Microfluidics, Microfluidics And Mem's, Microfluidics Dielectrophoresis, Microfluidics Multi-Band Device, Microfluidics Nanosphere, near-infrared laser, photolithography-free fabrication, research instrumentation, scalable platform, single cell analysis, single cell analysis and testing, Single cell data, single-cell handling, single-cell manipulation, single-cell resolution, single-cell trapping

Category(s): Chemical, Chemical > Chemical Processing & Manufacturing, Chemical > Instrumentation & Analysis, Diagnostic Markers, Diagnostic Markers > Targets And Assays, Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Life Science Research Tools, Life Science Research Tools > Lab Equipment, Life Science Research Tools > Microfluidics And Mems, Life Science Research Tools > Research Methods, Mechanical, Mechanical > Instrumentation, Platforms, Platforms > Diagnostic Platform Technologies

Generation of Therapeutic Human Anti-Trop-2 Extracellular Domain Antibodies (UCLA Case No. 2026-026)

UCLA researchers from the Department of Molecular and Medical Pharmacology and the Department of Microbiology, Immunology and Molecular Genetics have developed a panel of human antibodies and chimeric antigen receptors targeting Trop-2, providing diagnostic and therapeutic resources for targeting Trop2-driven cancer. BACKGROUND: Trophoblast cell surface...

Published: 12/23/2025 | Updated: 12/23/2025 | Inventor(s): Tanya Stoyanova, Owen Witte

Keywords(s):

Category(s): Diagnostic Markers > Cancer, Diagnostic Markers > Targets And Assays, Life Science Research Tools > Antibodies, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Combination Metabolic-Epigenetic Treatment for Early Lung Cancer (UCLA Case No. 2022-247)

UCLA researchers in the Division of Pulmonary Medicine at the School of Medicine uncovered a novel mechanism by which cancer cells adapt to glucose restriction and develop treatment resistance, and have in response developed a novel combination therapy to delay lung adenocarcinoma development while circumventing the development of aggressive behavior...

Published: 10/23/2025 | Updated: 10/8/2025 | Inventor(s): Claudio Scafoglio

Keywords(s):

Category(s): Therapeutics > Oncology, Diagnostic Markers > Cancer

Combination of Insulin-like Growth Factor-1 Receptor (IGF1R) or Insulin Receptor Inhibitors with Immune Checkpoint Inhibitors in Management of Triple-Negative Breast Cancer (UCLA Case No. 2020-872)

UCLA researchers in the Department Joe C. Wen School of Nursing have developed a novel targeted therapy for triple-negative breast cancer with a potential synergy with immunotherapy. BACKGROUND: Triple-negative breast cancer (TNBC) accounts for about 10-15% of women with breast cancer (BC), but its mortality rate is disproportionally high, causing...

Published: 3/2/2026 | Updated: 10/6/2025 | Inventor(s): Nalo Hamilton

Keywords(s):

Category(s): Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Metabolism And Endocrinology, Diagnostic Markers > Cancer, Therapeutics > Women's Health

Double-Stranded RNA Expression Signatures to Predict Response to Cancer Therapy (UCLA Case No. 2022-218)

UCLA researchers from the Department of Integrative Biology and Physiology have developed a novel method to profile RNA editing in single cells from lung cancer biopsies as a method to predict patient survival. BACKGROUND: RNA editing occurs naturally in the human transcriptome and has been shown to influence cancer cell behavior and the anti-tumor...

Published: 9/17/2025 | Updated: 9/17/2025 | Inventor(s): Xinshu Xiao, Ting Fu

Keywords(s):

Category(s): Diagnostic Markers > Cancer, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

1 2